|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Asthma, COPD and Allergic Rhinitis - Weak Late Stage Pipeline Leaves Innovation to Phase I/II Candidates
Datamonitor, July 2004, Pages: 179
Following several successful drug launches to the respiratory market in the past five years, companies are seeking the next blockbuster drug in a high potential market.
While the late-stage pipeline is relatively sparse, a number of moderately successful launches will help bridge the gap between drugs like Advair and the high number of Phase I and Phase II therapies.
Scope of Report:
Evaluation of over 70 drugs in development for asthma, COPD, and allergic rhinitis.
Opinion leader insight into early stage therapies and treatment strategies, including recommendations for areas of focus
Forecasts of key late-stage therapies: Alvesco (ciclesonide), Daxas (roflumilast), Ariflo (cilomilast), arformoterol, and QAB-149
Detailed SWOT analysis of key compounds, and comparison to current gold standards
Report Highlights:
Multiple potential treatment pathways, an enormous patient population, and a relatively high level of unmet need in COPD have promoted a deep respiratory pipeline. However, among over 70 products in Phase I development or later, only six are in Phase III or registration.
PDE-4 inhibitors will be the next novel drug class to reach the respiratory market, with the launch of roflumilast and cilomilast over the next two years, but the superiority of Spiriva will likely lead to these second-to-market drugs battling for market share with xanthines and other add-on therapies.
With a number of novel therapies showing disappointing results, and many others without enough data to evaluate potential sales, few companies have developed drugs that have the potential to become the class standard. Among late-stage candidates in established classes, only Altana/Aventis's Alvesco (ciclesonide) is expected to attain high sales.
Reasons to Purchase:
Understand unmet needs in the respiratory market, and how late-stage compounds address these needs
Identify potential licensing opportunities for respiratory market entry or portfolio expansion
Benchmark key late-stage asthma and COPD compounds against market leaders
Customers who bought this item also bought
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
Pipeline Insight: Asthma, Copd and Allergic Rhinitis - The Needs of Severe Patients Must be Addressed
Pipeline Insight: Asthma/COPD/Allergic Rhinitis - As Patents Expire, Novel Combinations Inspire
Commercial and Pipeline Insight: Allergic Rhinitis
Pipeline Insight: Asthma/COPD - Targeted Therapies on the Horizon
Asthma And COPD - Get Smart
Asthma & COPD Therapeutics
Commercial Insight: Asthma & COPD - On the verge of generic entry
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Strategic Perspectives: Allergic Rhinitis - Impact of a blockbuster going bust
Asthma and COPD Drug Discoveries: What the Future Holds
|
|
|
|
